Shield Therapeutics (AIM: STX) is a revenue generating specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until 2035.
Iron Deficiency is a common complication of inflammatory bowel disease, and Shield Therapeutics have submitted for a broader label across Europe, which would allow them to treat all patients with IDA. Sheild therapeutics have identified a market opportunity of 30 million patients across Europe and the USA, with a peak sales opportunity of more than $500m.
Ferracru is differentiated from existing treatments as patients can take the pill without food. The delivery method also prevents patients from having to go on to intravenous iron which has to be given in a hospital setting.
Dr Andrew Heath (NE Chair) Deputy Chair and Senior Ind. Director of Oxford BioMedica plc and NED of Novacyt SA and IHT. Ex director of the BioIndustry Association and CEO of Protherics plc.
Carl Sterrit (CEO) 20 yrs management and executive level experience in pharma. Co-founded the Group in 2008 together with Dr.Christian Schweiger.
James Karis (NED) 35 yrs sector experience. Current CEO of privately held MAPI Group.
Peter Llewellyn-Davis (NED) 25 year track record in international M&A deals, company turnarounds, licensing transactions and financing activities with particular experience in chemical and healthcare industries.
Shield receives EU Commission approval for the broadening of the indication for Feraccru® (Ferric Maltol) to the treatment of Iron Deficiency in …
London, UK, 16 March 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, announces …
Shield Therapeutics (LON:STX), the AIM Listed developer and distributor of treatments for Iron Deficiency Anaemia, has received an endorsement from …
Shield Therapeutics have today announced their interim results. We filmed a brief update with Carl Sterrit which is available on …
|P&L||31 Dec 2016|
|31 Dec 2015
|Cost of Sales||(100)|
|Loss for the year||(9,042)||(6,140)
|P&L||31 Dec 2016|
|31 Dec 2015
|Cash & cash equivalents ||20,978||725
|Net asset/ (liabilities)||48,396||(18,643)
Allergy Thereapeutics plc (AIM:AGY)
Development & Manufacture of allergy vaccines
Maxcyte Inc (AIM:MXCT)
Revenue generating cell engineering technology
Tissue Regenix Group PLC (LON:TRX)
Development of regenerative medical technology
Quantum Pharma PLC (LON:QP)
Development & manufacture of niche pharmaceuticals
Bioventix PLC (LON:BVXP)
Development & manufacture of sheep monoclonal antibodies
Verona Pharma plc (LON:VRP)
Development of drugs to treat respiratory diseases
“A steady increase in the incidence of IBD has occurred..” Ebbe Langholz discussing the history of IBD – Current trends in inflammatory bowel disease: the natural history
“Iron deficiency anaemia (IDA) is a common complication of inflammatory bowel disease (IBD)”European Crohn’s and Colitis Organisation – Poor recognition and management of iron deficiency anaemia in inflammatory bowel disease: a missed opportunity
“Shield Therapeutics strikes significant deal to sell pioneering iron deficiency drug in Switzerland”
FinnCap (Sep 2017)
“Feraccru facing headwinds in UK and Germany with STX management quick to identify areas of weakness and reconfigure reporting lines centrally across sales regions. Tighter leverage of increased sales teams with specialist regional knowledge should bring Feraccru growth in the EU back on track quickly.”
Peel Hunt (Sep 2017)
“We understand the slower ramp-up in the UK and Germany vs management’s previous guidance is due to ongoing bureaucratic
delays in formulary decisions in England and slower recruitment of sales reps in Germany than Shield had anticipated. However, the company has taken steps to reallocate resource to drive commercial and clinical results without increasing fixed costs. Mid-term guidance for Feraccru revenues in Europe to reach £20m-25m remains unchanged and is consistent with our model.”